Daglozin^®

Therapeutic Segment:
Anti-diabetic

Generic Name:
Dapagliflozin

Description:
Dapagliflozin is described chemically as D-glucitol, 1,5-anhydro -1-C- [4-chloro-3-[ (4-ethoxyphenyl) methyl] phenyl]-, (1S)-, compounded with (2S)-1,2-propanediol, hydrate (1:1:1).

Indication:
Daglozin (dapagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, as monotherapy (if metformin inappropriate). Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control). Limitations of Use: Daglozin is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Contraindications: Ketoacidosis, History of a serious hypersensitivity reaction to Daglozin. Severe renal impairment, (eGFR less than 30 mL/min/1.73 m2) end-stage renal disease (ESRD), or patients on dialysis.

Formulation:

• Tablets

Strength:

• 5mg
• 10mg

Pack Size:

• 10’s